Document Detail


Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells.
MedLine Citation:
PMID:  20799280     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malignant mesothelioma is an aggressive tumor of serosal surfaces, which is refractory to current treatment options. Arsenic trioxide (As2O3) is used clinically to treat acute promyelocytic leukemia, and also to inhibit proliferation of several solid tumors including hepatoma, esophageal, and gastric cancer in vitro. Here we found that As2O3 inhibited cell viability of a mesothelioma cell line, NCI-H2052. As2O3 induced apoptosis of NCI-H2052 cells, which was accompanied by activation of c-Jun NH2-terminal kinase (JNK)1/2, extracellular signal-regulated kinase (ERK)1/2, and caspase-3. zVAD-fmk, a broad-spectrum caspase inhibitor, inhibited As2O3-induced apoptosis and activation of caspase-3, but not that of JNK1/2 and ERK1/2. Small interfering RNAs (siRNAs) targeting JNK1/2 suppressed As2O3-induced caspase-3 activation and apoptosis, indicating that JNK1/2 regulate As2O3-induced apoptosis though caspase cascade. Furthermore, JNK1 siRNA abrogated As2O3-induced JNK2 phosphorylation and JNK2 siRNA abrogated As2O3-induced JNK1 phosphorylation, suggesting that JNK1 and JNK2 interact with each other. Moreover, JNK1 siRNA, but not JNK2 siRNA, abrogated As2O3-induced ERK1/2 phosphorylation. JNK2 siRNA together with PD98059, a specific MAPK/ERK kinase inhibitor, suppressed As2O3-induced apoptosis more significantly than JNK2 siRNA alone. These results indicated that As2O3 induces apoptosis of NCI-H2052 cells mainly through JNK1/2 activation, and that ERK1/2 is involved in As2O3-induced apoptosis when JNK1/2 are inactivated.
Authors:
Ryoji Eguchi; Yoshihiro Fujimori; Hiromi Takeda; Chiharu Tabata; Toshiro Ohta; Kouzo Kuribayashi; Kazuya Fukuoka; Takashi Nakano
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cellular physiology     Volume:  226     ISSN:  1097-4652     ISO Abbreviation:  J. Cell. Physiol.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2010-12-30     Completed Date:  2011-01-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0050222     Medline TA:  J Cell Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  762-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Wiley-Liss, Inc.
Affiliation:
Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis / drug effects*
Arsenicals / pharmacology*
Caspases / metabolism
Cell Line, Tumor
Drug Screening Assays, Antitumor
Enzyme Activation / drug effects
Extracellular Signal-Regulated MAP Kinases / metabolism*
Humans
JNK Mitogen-Activated Protein Kinases / metabolism*
Mesothelioma / enzymology*,  pathology*
Mitogen-Activated Protein Kinase 1 / metabolism
Mitogen-Activated Protein Kinase 3 / metabolism
Mitogen-Activated Protein Kinase 8 / metabolism
Mitogen-Activated Protein Kinase 9 / metabolism
Oxides / pharmacology*
Chemical
Reg. No./Substance:
0/Arsenicals; 0/Oxides; 1327-53-3/arsenic trioxide; EC 2.7.1.24/Mitogen-Activated Protein Kinase 9; EC 2.7.11.24/Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24/JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24/Mitogen-Activated Protein Kinase 1; EC 2.7.11.24/Mitogen-Activated Protein Kinase 3; EC 2.7.11.24/Mitogen-Activated Protein Kinase 8; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blood-derived human osteoclast resorption activity is impaired by Hyaluronan-CD44 engagement via a p...
Next Document:  Complexity of polycomb group function: Diverse mechanisms of target specificity.